ARTICLE | Clinical News
Invega paliperidone ER regulatory update
May 5, 2014 7:00 AM UTC
EMA's CHMP recommended expanding the label of Johnson & Johnson's Invega paliperidone to treat schizophrenia to include adolescents ages >=15 years. The metabolite of J&J's Risperdal risperidone, an ...